ReviewFrontiers in endocrinology2026
The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectives.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Dual activation of MC3R and MC4R drives weight loss and reduces food intake in male primates with obesity.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The melanocortin system is a genetically conserved and clinically validated target for the treatment of obesity. Hundreds of studies establish the role of the melanocortin receptors, particularly the melanocortin-4 receptor, in food intake, weight control, and energy expenditure. Over the last several decades, the pharmaceutical industry pursued melanocortin-4 receptor-selective agonists for the treatment of general obesity. Many candidates failed to demonstrate meaningful weight loss in the clinic due to potency, selectivity or side effect profiles, leading pharmaceutical companies to dismiss the use of melanocortin compounds for treating general obesity. Recent advancements in the field demonstrate the importance of modulating both melanocortin-3 and -4 receptors for optimal weight loss and offer solutions to mitigate undesired side effects associated with melanocortin agonism. Considering these discoveries, it is imperative to review past clinical attempts and compare them with programs currently in development. A thorough understanding of the shortcomings of past clinical programs will enable the development of novel melanocortin therapeutics for the treatment of general obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.